Daiichi Sankyo Europe GmbH

Featured Stories

For the last nine years Daiichi Sankyo has supported young graduates in Pharmaceutical Sciences from the Ludwig-Maximilians-University in Munich (LMU). In 2017, Kristina Eiglmeier and Martin Müller were awarded the "Master Prize" read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
04/04/2018 Research	Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative	PDF
27/03/2018 Research	Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW	PDF
07/03/2018 Research	Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer	PDF
22/02/2018 Research	Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer	PDF
06/02/2018 Research	Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support for Young Talents

Value Report 2017